Cytopath smear other source
CPT code 88160 covers the laboratory examination of cells collected from body sites other than the cervix, such as respiratory secretions, urine, or body fluids, to detect abnormalities or disease.
This calculator gives a typical-case estimate using standard Medicare modifier rules. Actual payment depends on payer policies, documentation, code-specific CMS status indicators, and locality. Verify before billing.
RVU breakdown
Conversion factor: 32.3465 · Source: CMS MPFS RVU25A · Confidence: High
NCCI bundling edits
Loading bundling edits…
Billing tips
Bill one unit per specimen source, not per slide prepared. Multiple slides from the same anatomic site during the same collection constitute one billable unit.
Impact: Prevents overbilling denials and potential fraud investigations; ensures compliance with Medicare's one-unit-per-specimen policy
Document the specific anatomic source in the pathology report (e.g., 'sputum,' 'urine,' 'pleural fluid') as generic descriptions may trigger medical necessity denials.
Impact: Reduces denial rate by 30-40% for medical necessity and improves clean claim rate on first submission
Use 88160 for screening-level cytology; upgrade to 88173-88177 when physician interpretation with written report is required for non-gynecologic specimens.
Impact: 88173 reimburses at $123.86 vs $80.87 for 88160, representing 53% higher payment when appropriate
Ensure CLIA certification is current and matches the complexity level of testing performed; cytopathology requires moderate or high complexity certification.
Impact: Prevents 100% denial of all claims if laboratory lacks proper CLIA certification for cytology services
When specimens are inadequate for diagnosis, still bill 88160 with appropriate ICD-10 code and note specimen inadequacy in report; the service was rendered.
Impact: Captures $80.87 reimbursement for work performed even when specimen quality prevents definitive diagnosis
Link appropriate ICD-10 codes indicating medical necessity (signs/symptoms or screening based on risk factors) rather than generic 'screening' codes without justification.
Improves initial acceptance rate by 25-35% and reduces secondary review requests from payers
Real billers contribute denial patterns and appeal strategies for this code. Once 5+ reports come in, you’ll see live aggregated data here — the only place this exists, free.
Get the free Revenue Protection Toolkit — the denial triggers, modifier pitfalls, and bundling conflicts that quietly cost you reimbursement. Instant download.
Help build the field knowledge
MedPayIQ gets smarter as billers contribute. If you've had this code denied, share what happened so others learn from it. Anonymous, no patient info.